Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
出版年份 2020 全文链接
标题
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
作者
关键词
-
出版物
Nature Communications
Volume 11, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-09-14
DOI
10.1038/s41467-020-18442-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
- (2019) Rashmi R. Shah et al. DRUG SAFETY
- AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- (2019) Hirokazu Taniguchi et al. Nature Communications
- FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes
- (2019) Elizabeth J. Adams et al. NATURE
- Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer
- (2019) Abhijit Parolia et al. NATURE
- Patient‐derived xenograft models of non‐small cell lung cancer for evaluating targeted drug sensitivity and resistance
- (2019) Kenji Kita et al. CANCER SCIENCE
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
- (2018) Zofia Piotrowska et al. Cancer Discovery
- ChIP‐Atlas: a data‐mining suite powered by full integration of public ChIP‐seq data
- (2018) Shinya Oki et al. EMBO REPORTS
- Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
- (2017) Chao-Chi Ho et al. Journal of Thoracic Oncology
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer
- (2017) Shinji Kohsaka et al. Science Translational Medicine
- Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
- (2017) Aaron Simpson et al. Targeted Oncology
- Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
- (2016) Yoshihisa Kobayashi et al. CANCER SCIENCE
- Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
- (2016) S. Ortiz-Cuaran et al. CLINICAL CANCER RESEARCH
- Differential Roles of Insulin and IGF-1 Receptors in Adipose Tissue Development and Function
- (2016) Jeremie Boucher et al. DIABETES
- Essential Role of IGFIR in the Onset of Male Brown Fat Thermogenic Function: Regulation of Glucose Homeostasis by Differential Organ-Specific Insulin Sensitivity
- (2016) Vanesa Viana-Huete et al. ENDOCRINOLOGY
- MEG3 Long Noncoding RNA Contributes to the Epigenetic Regulation of Epithelial-Mesenchymal Transition in Lung Cancer Cell Lines
- (2016) Minoru Terashima et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Nucleation of DNA repair factors by FOXA1 links DNA demethylation to transcriptional pioneering
- (2016) Yu Zhang et al. NATURE GENETICS
- Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
- (2016) H. Kitai et al. Cancer Discovery
- Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy inEGFR-Mutant Lung Cancer: A Meta-Analysis
- (2015) Chee Khoon Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
- (2015) Martin Fassnacht et al. LANCET ONCOLOGY
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2015) Lecia V. Sequist et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
- (2014) M. Raymond V. Finlay et al. JOURNAL OF MEDICINAL CHEMISTRY
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Tumour heterogeneity and cancer cell plasticity
- (2013) Corbin E. Meacham et al. NATURE
- Multiplex Genome Engineering Using CRISPR/Cas Systems
- (2013) L. Cong et al. SCIENCE
- Tumor heterogeneity in the clinic: is it a real problem?
- (2013) Filip Janku Therapeutic Advances in Medical Oncology
- Cancer genetics and genomics of human FOX family genes
- (2012) Masuko Katoh et al. CANCER LETTERS
- Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
- (2012) A. B. Cortot et al. CANCER RESEARCH
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- CTCFBSDB 2.0: a database for CTCF-binding sites and genome organization
- (2012) Jesse D. Ziebarth et al. NUCLEIC ACIDS RESEARCH
- Pioneer transcription factors: establishing competence for gene expression
- (2011) K. S. Zaret et al. GENES & DEVELOPMENT
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor
- (2009) Mark J Mulvihill et al. Future Medicinal Chemistry
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
- (2008) S. Yano et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More